Abbott stock dives after company gives gloomy outlook, despite earnings beat
Abbott Laboratories fell in early trading after it lowered its full-year outlook, despite posting second-quarter earnings that beat Wall Street estimates.
The company now expects to report full-year earnings per share between $5.10 and $5.20, down from its earlier guidance of $5.05 to $5.25 a share. Shares fell 6% in premarket trading.
The company reported second-quarter earnings of $1.26 a share, edging just above the $1.25 that analysts polled by FactSet were expecting. It also reported $11.1 billion in revenue, in line with expectations.